Rheumatoid Arthritis Donor PBMCs: Shared Epitope, Th17 Pathology, and RA Research

Reviewed by the OrganaBio scientific team.

What makes RA immunology accessible from peripheral blood

Rheumatoid arthritis is the most prevalent systemic autoimmune disease, and its immune pathology is unusually well characterised from the peripheral blood compartment. Anti-citrullinated protein antibodies (ACPA, measured clinically as anti-CCP) and rheumatoid factor are detectable in serum years before clinical onset, and in seropositive donors the ACPA-producing B cells and citrulline-specific helper T cells circulate in peripheral blood. The cells that matter are present, characterised in the literature, and available at the density functional assays need.

That accessibility is also the limit, and it is worth stating plainly before anyone designs around it. Peripheral blood is not synovium. The synovial compartment concentrates the pathology: tissue-resident memory T cells, activated fibroblast-like synoviocytes, and a cytokine milieu that peripheral blood only partially reflects. What RA donor PBMCs give you is a systemically primed immune compartment from someone whose disease is real, which is a categorically better model than a healthy donor and a categorically worse one than synovial tissue. Programmes that treat it as the former get useful data. Programmes that treat it as the latter get surprised at the next stage.

ACPA biology and the shared epitope

ACPA are present in roughly 70 per cent of RA patients and are both diagnostic and pathogenic. They target proteins modified by peptidylarginine deiminases, enzymes that convert arginine residues to citrulline. That post-translational modification creates neo-epitopes which were never present during thymic selection, so tolerance was never established against them.

The genetic basis sits in HLA-DRB1. Alleles encoding the shared epitope, principally DRB1*04:01, *04:04, *04:05, *01:01 and *01:02, present citrullinated peptides to CD4+ T cells with high affinity, and the shared epitope is carried by approximately 70 per cent of ACPA-positive patients. For antigen-specific work this is the whole game: staining shared-epitope-positive donor PBMCs with citrullinated peptide-MHC class II tetramers identifies the antigen-specific CD4+ population directly, without the expansion artefacts that in vitro stimulation introduces.

OrganaBio provides high-resolution NGS HLA typing across HLA-A, B, C, DR, DQ and DP on donor material, so the DRB1 data needed to determine shared-epitope status is in the documentation. Whether a cohort can be assembled to a particular allele specification is a question of what is in inventory at the time, and the scientific team answers it per request rather than from a published list.

Seropositive and seronegative RA are two different cohorts

This is the design decision most requests skip. Roughly 30 per cent of RA patients are ACPA-negative, and seronegative RA is not simply milder seropositive disease. It has a different genetic association, a weaker shared-epitope link, a different response profile to B-cell-directed therapy, and increasingly it is treated in the literature as a distinct entity rather than a subgroup.

The practical consequence: a cohort assembled without regard to serostatus is a mixture of two populations, and any effect size measured across it is diluted by whichever population does not carry the biology being tested. If the target is ACPA-driven, the cohort has to be seropositive and the design has to say so. If the programme is testing something downstream of serostatus entirely, a mixed cohort is fine and cheaper. Deciding which of those is true is a five-minute conversation that saves a study.

Th17, and the three cytokine axes with drugs attached

The RA synovium is dominated by a Th17 and Th1 cytokine environment. IL-17A, IL-1β, TNF-α, IL-6 and GM-CSF drive synovial fibroblast activation, osteoclastogenesis and cartilage destruction. Peripheral blood T cells from RA donors carry the Th17-skewed effector memory phenotype that reflects it.

Three axes matter most, because each has approved or late-stage drugs against it, which means each has an assay someone is trying to run.

• IL-6 and IL-6R. IL-6 drives Th17 differentiation and the acute-phase response. Tocilizumab and sarilumab are approved. RA donor PBMCs carry elevated IL-6 secretion at baseline and after TLR stimulation, which is the pharmacodynamic context an IL-6 pathway inhibitor needs.
• JAK and STAT. JAK1, JAK2, JAK3 and TYK2 carry signalling from IL-6, IL-12, IL-15, IFN-γ and GM-CSF. Tofacitinib, baricitinib, upadacitinib and filgotinib are approved for RA. RA donor PBMCs show elevated baseline phospho-STAT1, STAT3 and STAT6 from constitutive signalling, so a JAK inhibitor dose-response can be run without exogenous cytokine priming. Healthy donor PBMCs have to be artificially stimulated to approximate a state RA cells arrive in.
• GM-CSF. GM-CSF drives myeloid activation in the synovium, and anti-GM-CSF and anti-GM-CSFR antibodies including mavrilimumab and otilimab are in late-stage development. RA donor monocytes show enhanced monocyte-to-macrophage differentiation responses relevant to that axis.

Treg dysfunction, and why healthy effectors hide it

RA Tregs show a dissociation that matters for anyone running suppression assays: CD4+CD25+FoxP3+ frequency in peripheral blood is close to normal, while suppressive function is measurably impaired. The suppression curve shifts right, so a higher Treg to effector ratio is needed to reach equivalent suppression. Two mechanisms are described: TNF-α signalling through TNFR2 destabilising FoxP3, and IL-2 deprivation in the inflamed environment removing the primary Treg survival signal.

The assay design consequence is specific. Run RA Tregs against healthy donor effectors and the deficit largely disappears, because healthy effectors are easy to suppress. The deficit shows up when the effector population is also RA-derived, Th17-skewed, and assayed in the presence of TNF-α and IL-6. For a Treg cell therapy programme aimed at RA, that is the assay that predicts anything, and it needs donor material on both sides of it.

Osteoclastogenesis from RA donor monocytes

Osteoclasts, the multinucleated bone-resorbing cells behind the erosive joint destruction characteristic of RA, derive from monocyte and macrophage precursors under RANKL and M-CSF. RA donor monocytes differentiate into osteoclasts more readily than healthy donor monocytes, reflecting in vivo priming from elevated RANKL signalling in the RA environment.

For programmes targeting bone erosion, whether anti-RANKL, cathepsin K inhibition, or JAK inhibition for bone preservation, that primed precursor pool is the substrate the assay is supposed to model. If the monocyte fraction is what the work needs rather than whole PBMCs, CD14+ monocytes are a separate catalogue product from healthy donors, and disease-state monocyte isolation is a custom request.

What is documented, and what to ask for

Every RA donor lot is enrolled under an IRB-approved protocol with a verified clinical diagnosis, and ships with disease history, treatment background, inclusion and exclusion criteria compliance, demographic profile, and high-resolution NGS HLA typing. Standard configuration is 1.0 × 10⁷ cells per vial, cryopreserved. Custom cell counts, fresh format and specific donor criteria are available on request. Donors are also screened against 14 infectious disease markers under 21 CFR 1271 donor eligibility criteria.

What is worth raising before you order, because the answer depends on current inventory rather than a catalogue field: serostatus if the design is ACPA-dependent, shared-epitope allele status if the work is tetramer-based, treatment background if drug exposure is a confounder or the point, and whether the study needs more than one cell type from the same person. Donor-matched material across cell types and matched plasma or serum from the same collection is one of the things a vertically integrated supplier can do that a reseller cannot, and it is worth asking about early rather than discovering it was possible after the cohort is fixed.

Disease-state material is supplied for research and discovery use only. It is not GMP starting material for clinical manufacturing, and any autoimmune cell therapy heading toward the clinic uses the patient’s own apheresis for that purpose.

Questions researchers ask

What is the shared epitope and why does it matter for RA research?

The shared epitope is a conserved amino acid sequence in the third hypervariable region of the HLA-DRB1 chain, encoded by alleles including *04:01, *04:04, *04:05, *01:01 and *01:02. These alleles present citrullinated peptides to CD4+ T cells with high affinity, which drives ACPA production and T cell autoreactivity, and roughly 70 per cent of ACPA-positive RA patients carry one. Antigen-specific work using citrullinated peptide-MHC class II tetramers requires shared-epitope-positive donors. OrganaBio provides high-resolution NGS HLA typing including DRB1, so the allele data is in the documentation; whether a cohort can be assembled to a specific allele is confirmed against current inventory.

Should my cohort be ACPA-positive, ACPA-negative, or mixed?

It depends on whether the biology under test is downstream of serostatus. Around 30 per cent of RA patients are ACPA-negative, and seronegative RA has a different genetic association and a different response profile to B-cell-directed therapy, so it behaves as a distinct population rather than milder disease. If the target is ACPA-driven, a mixed cohort dilutes the effect. If the readout sits downstream of serostatus, a mixed cohort is acceptable and easier to assemble. Raise it with the scientific team before the cohort is fixed.

Why are RA donor PBMCs better than healthy PBMCs for JAK inhibitor assays?

RA donor PBMCs carry elevated baseline phospho-STAT1, STAT3 and STAT6 from constitutive IFN-gamma, IL-6 and IL-4 signalling, so a JAK inhibitor dose-response measuring phospho-STAT inhibition can be run on the cells as they arrive. Healthy donor PBMCs lack that baseline and have to be primed with exogenous cytokine to approximate it, which introduces a stimulation artefact into the very readout the assay depends on.

Why does a Treg suppression assay need RA effector cells as well as RA Tregs?

Because healthy donor effector T cells are easy to suppress, so a functional Treg deficit largely disappears against them. The impairment seen in RA, a rightward shift in the suppression curve requiring higher Treg to effector ratios, shows up when the effector population is also RA-derived and Th17-skewed and the assay runs in the presence of TNF-alpha and IL-6. For a Treg therapy programme aimed at RA, that is the assay with predictive value.

Can RA donor material be used for osteoclastogenesis assays?

Yes. Monocytes from RA donors differentiate into osteoclasts more readily than healthy donor monocytes under RANKL and M-CSF, reflecting in vivo priming from elevated RANKL signalling. That makes them the relevant substrate for programmes targeting bone erosion pathways. If the work needs an isolated monocyte fraction rather than whole PBMCs, discuss it as a custom request, since the catalogue CD14+ monocyte product is from healthy donors.

What documentation ships with RA donor PBMCs?

Verified clinical diagnosis under an IRB-approved protocol, disease history, treatment background, inclusion and exclusion criteria compliance, demographic profile, high-resolution NGS HLA typing, and screening against 14 infectious disease markers under 21 CFR 1271 donor eligibility criteria. Standard configuration is 1.0 x 10^7 cells per vial, cryopreserved, with custom cell counts, fresh format and specific donor criteria available on request. Selection against a particular serology titre, disease-activity score or drug cohort is a feasibility question for the scientific team rather than a published catalogue field.

Is RA donor material suitable for clinical manufacturing?

No. OrganaBio disease-state donor material is supplied for research and discovery use only, covering drug screening, assay development and process development. An autoimmune cell therapy heading toward the clinic uses the patient’s own apheresis as GMP starting material, not donor material from a catalogue.

Related reading

• RA donor portfolio, cell populations and formats
• The joint environment healthy donor cells will never model
• Disease-state against healthy donor PBMCs
• Disease-state PBMCs across all 24 indications

Scope an RA donor request

Say what the assay measures, whether serostatus or HLA drives the design, how many donors the study needs, and when. The scientific team will confirm what is available against those criteria, and will tell you when a design depends on something the donor programme cannot reliably supply.

Talk with the scientific team or review the RA donor PBMC record.